View our masking and visitation guidelines based on current rates of respiratory illnesses in the community.

Our new building on the hospital campus, Forest B, is open. Families and visitors can park in the new Forest B garage next to Emergency.

Clinical Trial Search block Test

FH9716 Phase I study of adoptive immunotherapy with CD8+ and CD4+ memory T cells transduced to express an HA-1-specific T cell receptor (TCR) for children and adults with recurrent acute leukemia after allogeneic hematopoietic stem cell transplantation (HCT).

RG9217022 FH 9716

Condition(s): Leukemia, other, Lymphoid Leukemia, Myeloid and Monocytic Leukemia
Phase: I
Clinicaltrials.gov ID: NCT03326921

What is the goal of the study?

To evaluate the feasibility and safety of administration of HA-1 TCR T cell immunotherapy to children and adults with recurrent acute leukemia after allogeneic HCT

Who can participate in the study?

Everyone

Study Team:

PI (Study Doctor): Elizabeth Krakow
Study Team Member: Elizabeth Frecker, elizabeth.frecker@seattlechildrens.org